If you are interested in keeping up to date with stocks making moves within the biotech, pharma, and healthcare industries and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?The stock of Agios Pharmaceuticals, Inc. ( AGIO ) has hit the skids in trading today - down 49% at the time of writing, trading at $23 per share, which translates to a market cap valuation of ~$1.4bn.Edmund Ingham ...

PresentationGood morning, and welcome to the Agios Pharmaceuticals Investor Conference Call and Webcast. [Operator Instructions] Please be advised that this call is being recorded at Agios' request. I would now like to turn the call over to Morgan Sanford, Head of Investor Relations at Agios. Please go ahead.Morgan Sanford Thank you, operator. Good morning, everyone. Thank you for joining us to discuss top line results from the pivotal Phase III RISE UP trial of mitapivat for the treatment of sickle cell di ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 0.2% on Wednesday.The Dow traded down 0.23% to 45,985.50 while the NASDAQ gained 0.19% to 22,475.54. The S&P 500 also rose, gaining, 0.08% to 6,622.69.Check This Out: How To Earn $500 A Month From Walmart Stock Ahead Of Q3 EarningsLeading and Lagging SectorsCommunication services shares rose by 0.8% on Wednesday.In trading on Wednesday, energy stocks fell by 1.6%.Top HeadlineLowe's Companies, Inc. (NYSE:LOW) shares gain ...

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.AGIO is testing key support levels. See what the experts say hereThe trial met its primary endpoint of hemoglobin response, with mitapivat demonstrating a statistically significant improvement compared to placebo.Also Read: FDA Delays Decision On Agios Pharmaceuticals’ Blood Disorder Drug For Expanded UseDataWhile mitapivat also showed ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Agios Pharmaceuticals (NasdaqGS:AGIO) Update / Briefing November 19, 2025 08:00 AM ET Company ParticipantsEllen Horste - Equity Research AssociateSarah Gheuens - Chief Medical Officer and Head of Research and DevelopmentBrian Goff - CEOMorgan Sanford - Head of Investor RelationsBiree Andemariam - Professor of MedicineConference Call ParticipantsTessa Romero - Senior Analyst of Biotechnology Equity ResearchEmily Bodnar - Biotech Equity Research AnalystEric Smith - Senior Biotechnology AnalystLuca Issi - Seni ...

Agios Pharmaceuticals said on Wednesday its sickle cell drug met one of its two main goals in a late-stage study of patients aged 16 and older, but failed to show a statistically significant reduction... ...

Forward-looking statements Topline results Phase 3 RISE UP in sickle cell disease November 19, 2025 This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the potential benefits of mitapivat; Agios' plans for future meetings with, or submissions to, regulators, including the FDA; Agios' plans for the development of mitapivat, t ...

Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in primary endpoint of annualized rate of SCPCs (pain crises), and the key secondary endpoint of change from baseline in PROMIS Fatigue was not met Patients in the mitapivat arm who achieved hemoglobin response had clinically meaningful benefits in SCPC-related endpoints and PRO ...

根据提供的文档内容，该文档不包含任何与公司或行业相关的实质性信息 无法完成新闻要点总结